A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ZnAg Liquid Solution to Treat COVID-19 in Acutely Symptomatic Non-Hospitalized Participants
Latest Information Update: 10 Feb 2023
At a glance
- Drugs CNM AgZn17 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Clene Nanomedicine
- 06 Feb 2023 Status changed from active, no longer recruiting to completed.
- 27 Dec 2022 Primary endpoint has not been met. (The proportion of participants who require COVID-19 related hospitalization, are hospitalized for COVID-19 related medical support, or are deceased within 28-days following randomization.), according to Clene Inc media release.
- 27 Dec 2022 Top-line results published in a Clene Inc media release.